Clinical Trial

Disease: Phenylketonuria, PKU, (NCT04768348)

Disease info:

Phenylketonuria (PKU) is an inherited metabolic disorder caused by an absence or deficiency of the enzyme phenylalanine hydroxylase (PAH). The disorder is easily detectable via routine newborn screening and treatment usually begins immediately.

PAH is responsible for processing the enzyme phenylalanine, one of the amino acids vital for normal growth and development. In individuals with PKU, PAH fails to convert phenylalanine into tyrosine leading to an accumulation of toxic phenylalanine in the blood and brain. The direct toxic effect of phenylalanine can lead to severe intellectual disability and other symptoms.

Frequency:
The exact disease frequency is unknown but is estimated to be about 1 in every 15,000 births.
Official title:
A Prospective Study Investigating the Natural History of Adults With Phenylketonuria (PKU) Due to Phenylalanine Hydroxylase Deficiency
Who:
Partners:
Locations:

United States, California Los Angeles, California, United States, 90027 Recruiting Kaiser Permanente Los Angeles Medical Center

United States, California Orange, California, United States, 92868 Recruiting Children's Hospital of Orange County

United States, Florida Tampa, Florida, United States, 33606 Recruiting University of South Florida

United States, Georgia Atlanta, Georgia, United States, 30322 Recruiting Emory University Hospital

United States, Indiana Topeka, Indiana, United States, 46571 Recruiting Community Health Clinic

United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15224 Recruiting University of Pittsburgh Medical Center- CHOP

United States, Texas Dallas, Texas, United States, 75390 Recruiting UT Southwestern Medical Center

United States, Utah Salt Lake City, Utah, United States, 84018 Recruiting University of Utah Health

Study start:
Apr. 21, 2020
Enrollment:
7
Gene editing method:
NA
Type of edit:
NA
Gene:
Phenylalanine hydroxylase (PAH)
Delivery method:
NA
Note:
Observational trial
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Terminated

Description

Phenylalanine hydroxylase (PAH) deficiency is a rare disease caused by an inborn error of metabolism. If left untreated, PAH deficiency results in progressive, irreversible neurological impairment during infancy and early childhood.

This study is designed to collect information about important PKU-related symptoms and tests to characterize the natural history of PKU due to PAH deficiency in a selected sample of adults. No new investigational treatment will be administered to participating patients.

Last updated: Jun. 23, 2025
close
Search CRISPR Medicine